MedPath

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Phase 3
Recruiting
Conditions
Lymphoma, Mantle-Cell
Interventions
Registration Number
NCT04662255
Lead Sponsor
Loxo Oncology, Inc.
Brief Summary

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.

Detailed Description

This is a Phase 3 global, randomized, open-label study comparing pirtobrutinib (Arm A) to investigator's choice of ibrutinib, acalabrutinib or zanubrutinib (Arm B) in MCL patients who have received 1 or more lines of therapy and are BTK inhibitor naïve.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Confirmed MCL diagnosis
  • Previously treated with at least one prior line of systemic therapy for MCL
  • Measurable disease per Lugano criteria
  • Eastern Cooperative Oncology Group (ECOG) 0-2
  • Absolute neutrophil count ≥ 0.75 × 109/L without granulocyte-colony stimulating factor support within 7 days of screening
  • Hemoglobin ≥ 8 g/dL not requiring transfusion support or growth factors within 7 days of screening
  • Platelets ≥ 50 × 109/L not requiring transfusion support or growth factors within 7 days of screening.
  • AST and ALT ≤ 3.0 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN.
  • Creatinine clearance of ≥ 30 mL/min according to Cockcroft/Gault Formula
Exclusion Criteria
  • Prior treatment with an approved or investigational BTK inhibitor
  • History of bleeding diathesis
  • History of stroke or intracranial hemorrhage within 6 months of randomization
  • History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified T-cell (CAR-T) therapy within 60 days of randomization
  • Clinically significant cardiovascular disease
  • Prolonged QT interval corrected using Fridericia's formula (QTcF) > 470 ms on 2/3 consecutive ECGs, and mean QTcF>470 ms on all 3 ECGs
  • Known HIV infection or active HBV, HCV, or CMV infections. (Certain participants with controlled HBV infections may still be eligible)
  • Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption
  • Ongoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment.
  • Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.
  • Vaccination with live vaccine within 28 days prior to randomization

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)IbrutinibInvestigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)AcalabrutinibInvestigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)ZanubrutinibInvestigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
Arm A (Pirtobrutinib)PirtobrutinibOrally
Primary Outcome Measures
NameTimeMethod
To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)Up to approximately 24 months

Assessed per Lugano criteria

Secondary Outcome Measures
NameTimeMethod
To compare Overall Response Rate (ORR) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment armsUp to approximately 24 months

Assessed per Lugano criteria

To compare Overall Survival of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment armsUp to approximately 24 months

Assessed by survival

To compare Event Free Survival (EFS) as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment armsUp to approximately 24 months

Defined as the time from randomization to progressive disease (PD) or start of new treatment for MCL or withdrawal from trial due to toxicity or death

To compare Time to Treatment Failure (TTTF) as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment armsUp to approximately 24 months

Time from randomization to time when discontinuation criteria met

Time to worsening (TTW) of MCL-related symptomsUp to approximately 24 months

Using symptom questions identified from the European Organization for Research and Treatment of Cancer (EORTC) item library. The range of raw scores for these items could be from 0 to 52 with highest score being worse symptoms.

Comparative Tolerability as measured by proportion of time with high side effect burdenUp to approximately 24 months

Using 18 items covering 10 Patient Reported Outcome- Common Terminology Criteria for Adverse Events (PRO-CTCAE) concepts for frequency (0-5 with 5 as most frequent), and/or presence (0-1 with 1 being present), or Severity (0-5 with 5 as most severe) and/or presence (0-1 with 1 being present); these selective adverse events will be framed and then overall side effect burden will be ascertained with the Functional Assessment of Cancer Therapy (FACT) - Item GP5. The range of this item is 0 -4 with 4 as most bothersome.

To compare Duration of Response (DOR) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment armsUp to approximately 24 months

Assessed per Lugano criteria

Trial Locations

Locations (189)

Alaska Oncology and Hematology, LLC

🇺🇸

Anchorage, Alaska, United States

Arizona Oncology Associates, P.C. - HOPE

🇺🇸

Phoenix, Arizona, United States

UCLA Medical Center

🇺🇸

Los Angeles, California, United States

USO-Rocky Mountain Cancer Center

🇺🇸

Denver, Colorado, United States

Mayo Clinic in Florida

🇺🇸

Jacksonville, Florida, United States

Oncology-Hematology Associates of West Broward

🇺🇸

Tamarac, Florida, United States

Florida Cancer Specialists East

🇺🇸

West Palm Beach, Florida, United States

University of Kentucky Markey Cancer Center

🇺🇸

Lexington, Kentucky, United States

Mercy Health-Paducah Medical Oncology and Hematology

🇺🇸

Paducah, Kentucky, United States

Tulane Cancer Center Office of Clinical Research

🇺🇸

New Orleans, Louisiana, United States

Greenebaum Comprehensive Cancer Center

🇺🇸

Baltimore, Maryland, United States

DFCI Lymphoma

🇺🇸

Boston, Massachusetts, United States

Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Washington University Medical School

🇺🇸

Saint Louis, Missouri, United States

Columbia University Medical Center

🇺🇸

New York, New York, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Messino Cancer Center

🇺🇸

Asheville, North Carolina, United States

Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

Wake Forest University School of Medicine

🇺🇸

Winston-Salem, North Carolina, United States

Oncology Hematology Care Inc

🇺🇸

Cincinnati, Ohio, United States

Willamette Valley Cancer Institute & Research Ctr.

🇺🇸

Eugene, Oregon, United States

Sarah Cannon Research Institute SCRI

🇺🇸

Nashville, Tennessee, United States

Texas Oncology-Austin Midtown

🇺🇸

Austin, Texas, United States

Texas Oncology - Bedford

🇺🇸

Bedford, Texas, United States

University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Texas Oncology - McAllen

🇺🇸

McAllen, Texas, United States

Texas Oncology - Sherman

🇺🇸

Sherman, Texas, United States

US Oncology

🇺🇸

The Woodlands, Texas, United States

Texas Oncology - Tyler

🇺🇸

Tyler, Texas, United States

Huntsman Cancer Institute

🇺🇸

Salt Lake City, Utah, United States

University of Virginia Health System

🇺🇸

Charlottesville, Virginia, United States

USO-Virginia Cancer Specialists, PC

🇺🇸

Fairfax, Virginia, United States

Seattle Cancer Care Alliance

🇺🇸

Seattle, Washington, United States

University of Wisconsin Carbone Cancer Center

🇺🇸

Madison, Wisconsin, United States

Froedtert Memorial Lutheran Hospital

🇺🇸

Milwaukee, Wisconsin, United States

The St. George Hospital

🇦🇺

Kogarah, New South Wales, Australia

Royal Hobart Hospital

🇦🇺

Hobart, Tasmania, Australia

Linear Clinical Research

🇦🇺

Nedlands, Western Australia, Australia

Royal Perth Hospital

🇦🇺

Perth, Western Australia, Australia

Icon Cancer Care - The Wesley Medical Centre

🇦🇺

Auchenflower, Australia

Ordensklinikum Linz GmbH Elisabethinen

🇦🇹

Linz, Oberösterreich, Austria

Uniklinikum Salzburg

🇦🇹

Salzburg, Osterreich, Austria

Universitair Ziekenhuis Gent

🇧🇪

Gent, Oost-Vlaanderen, Belgium

AZ Delta

🇧🇪

Roeselare, West Flanders, Belgium

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

🇧🇪

Leuven, Belgium

Hospital São Lucas Copacabana

🇧🇷

Rio de Janeiro, CEP, Brazil

Hospital Beneficência Portuguesa de São Paulo

🇧🇷

São Paulo, CEP, Brazil

Centro de Oncologia e Hematologia do Ceará LTDA

🇧🇷

Aldeota, Fortaliza, Brazil

Hospital das Clínicas da UFGo - Goiânia

🇧🇷

Goiânia, Goiás, Brazil

Hospital Sao Domingos

🇧🇷

São Luís, MA, Brazil

Instituto Nacional de Câncer - INCA

🇧🇷

Rio de Janeiro, Rio De Jan, Brazil

Centro de Pesquisa Clínica São Lucas

🇧🇷

Campinas, Sau Paulo, Brazil

Fundação Faculdade Regional de Medicina de São José do Rio Preto, Dept. CIP - Centro Integrado de Pesquisa

🇧🇷

Rio Preto, SP, Brazil

Instituto de Ensino e Pesquisas São Lucas - IEP Hemomed

🇧🇷

Pacaembu, São Paulo, Brazil

CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

🇧🇷

Santo André, São Paulo, Brazil

A. C. Camargo Cancer Center

🇧🇷

Sao Paulo, São Paulo, Brazil

HC - UFPR - Hospital de Clínicas da Universidade Federal do Paraná

🇧🇷

Curitiba- PR, Brazil

Hospital da Clinicas da Faculdade de Medicina da USP

🇧🇷

Sao Paulo, Brazil

Hospital 9 De Julho

🇧🇷

Sao Paulo, Brazil

IPITEC

🇧🇷

São Paulo, Brazil

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

🇧🇷

São Paulo, Brazil

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

BC Cancer Vancouver

🇨🇦

Vancouver, British Columbia, Canada

Cancer Care Manitoba

🇨🇦

Winnipeg, Manitoba, Canada

Anhui Provincial Cancer Hospital

🇨🇳

Hefei, Anhui, China

Beijing ChaoYang Hospital

🇨🇳

Beijing, Beijing, China

Peking University First Hospital

🇨🇳

Beijing, Beijing, China

Peking University People's Hospital

🇨🇳

Beijing, Beijing, China

Beijing Cancer hospital

🇨🇳

Beijing, Beijing, China

Peking University Third Hospital

🇨🇳

Beijing, Beijing, China

Fujian Provincial Cancer Hospial

🇨🇳

Fuzhou, Fujian, China

Cancer Center of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center

🇨🇳

Guangzhou, Guangdong, China

Southern Medical University Nanfang Hospital

🇨🇳

Guangzhou, Guangdong, China

The First Affiliated Hospital of Henan University of Science &Technology

🇨🇳

Luoyang, Henan, China

Henan Cancer Hospital

🇨🇳

Zhengzhou, Henan, China

Wuhan Union Hospital

🇨🇳

Wuhan, Hubei, China

Yichang Central People's Hospital

🇨🇳

Yichang, Hubei, China

Hunan Cancer Hospital

🇨🇳

Changsha, Hunan, China

The First Affiliated Hospital of Soochow University

🇨🇳

Suzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University

🇨🇳

Nanchang, Jiangxi, China

Jilin Cancer Hospital

🇨🇳

Changchun, Jilin, China

Shengjing Hospital of China Medical University

🇨🇳

Shenyang, Liaoning, China

Fudan University Shanghai Cancer Center

🇨🇳

Shanghai, Shanghai, China

West China Hospital, Sichuan University

🇨🇳

Cheng Du, Sichuan, China

Tianjin Medical University Cancer Institute and Hospital

🇨🇳

Tianjin, Tianjin, China

Affiliated Tumor Hospital of Xinjiang Medical University

🇨🇳

Urumqi, Xinjiang, China

Zhejiang Cancer Hospital

🇨🇳

Hangzhou, Zhejiang, China

Lishui Central Hospital

🇨🇳

Lishui, Zhejiang, China

Chongqing Cancer Hospital

🇨🇳

Chongqing, China

Blood Institute of the Chinese Academy of Medical science

🇨🇳

Tianjin, China

Fakultni nemocnice Hradec Kralove

🇨🇿

Hradec Kralove, Hradec Králové, Czechia

Fakultni nemocnice Brno

🇨🇿

Brno, Czechia

Aarhus Universitetshospital, Aarhus Sygehus

🇩🇰

Aarhus N, Jutland, Denmark

Odense Universitetshospital

🇩🇰

Odense C, Syd, Denmark

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

🇫🇷

Bordeaux, Aquitaine, France

Hopital de la Pitie Salpetriere

🇫🇷

Paris, Cedex 13, France

Chu De Nancy Hop D'Adultes De Brabois

🇫🇷

Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

Hôpital Saint Vincent-de-Paul

🇫🇷

Lille, Nord-Pas-de-Calais, France

Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen

🇫🇷

Rouen, Seine-Maritime, France

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu

🇫🇷

Nantes, France

Institut Curie

🇫🇷

Paris, France

Centre hospitalier universitaire de Haut Leveque

🇫🇷

Pessac Cedex, France

Centre Hospitalier Lyon Sud

🇫🇷

Pierre Benite Cedex, France

Pole Regionalde Cancérologie(CHU de Poitiers)

🇫🇷

Politiers, France

CHRU De Tours

🇫🇷

Tours Cedex, France

Universitätsklinikum Ulm

🇩🇪

Ulm, Baden-Württemberg, Germany

Klinikum der Universität München Großhadern

🇩🇪

Würzburg, Bayern, Germany

Universitätsklinikum Gießen und Marburg GmbH

🇩🇪

Gießen, Hessen, Germany

Universitätsklinikum Münster - Albert Schweitzer Campus

🇩🇪

Münster, Nordrhein-Westfalen, Germany

InVO Institut für Versorgungsforschung in der Onkologie

🇩🇪

Koblenz, Rheinland-Pfalz, Germany

Universitätsmedizin Johannes Gutenberg Universität Mainz

🇩🇪

Mainz, Rheinland-Pfalz, Germany

Universitätsklinikum Schleswig-Holstein

🇩🇪

Lübeck, Schleswig-Holstein, Germany

OncoResearch Lerchenfeld GmbH

🇩🇪

Hamburg, Germany

Bnai Zion Medical Center

🇮🇱

Haifa, Israel

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

Chaim Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Tel Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Presidio Ospedaliero Civile Santi Antonio e Biagio

🇮🇹

Alessandria, AL, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

🇮🇹

Meldola, Emilia-Romagna, Italy

Ospedale Santa Maria delle Croci

🇮🇹

Ravenna, Emilia-Romagna, Italy

Ospedale San Raffaele

🇮🇹

Milano, Lombardia, Italy

IRCCS - AOU di Bologna

🇮🇹

Bologna, Italy

IRCCS Ospedale Policlinico San Martino

🇮🇹

Genova, Italy

Ospedale Vincenzo Cervello

🇮🇹

Palermo, Italy

Irccs Crob

🇮🇹

Potenza, Italy

Arcispedale Santa Maria Nuova

🇮🇹

Reggio Emilia, Italy

Ospedale Di Circolo E Fondazione Macchi

🇮🇹

Varese, Italy

Nagoya Medical Center

🇯🇵

Nagoya, Aichi, Japan

Nagoya City University Hospital

🇯🇵

Nagoya, Aichi, Japan

Hokkaido University Hospital

🇯🇵

Sapporo, Hokkaido, Japan

Kobe City Medical Center General Hospital

🇯🇵

Kobe, Hyogo, Japan

Tohoku University Hospital

🇯🇵

Sendai-shi, Miyagi, Japan

Kindai University Hospital

🇯🇵

Osaka Sayama-shi, Osaka, Japan

Saitama Medical Center

🇯🇵

Kawagoe, Saitama, Japan

Japanese Foundation for Cancer Research

🇯🇵

Koto, Tokyo, Japan

Chugoku Central Hospital

🇯🇵

Hiroshima, Japan

Kumamoto University Hospital

🇯🇵

Kumamoto, Japan

Kyoto Furitsu Medical University Hospital

🇯🇵

Kyoto, Japan

Okayama University Hospital

🇯🇵

Okayama, Japan

Gachon University Gil Medical Center

🇰🇷

Namdong-gu, Incheon-gwangyeoksi [Incheon], Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Korea, Republic of

Kosin University Gospel Hospital

🇰🇷

Busan, Seogu, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of

Bravis Ziekenhuis

🇳🇱

Bergen op Zoom, Noord-Brabant, Netherlands

Ziekenhuisapotheek HagaZiekenhuis

🇳🇱

Den Haag, Netherlands

Erasmus Medisch Centrum

🇳🇱

Rotterdam, Netherlands

Christchurch Hospital

🇳🇿

Addington, Christchurch, New Zealand

Middlemore Clinical Trials

🇳🇿

Auckland, New Zealand

Centrum Onkologii Ziemi Lubelskiej

🇵🇱

Lublin, Lubelskie, Poland

Uniwersyteckie Centrum Kliniczne

🇵🇱

Gdansk, Poland

Pratia MCM Krakow

🇵🇱

Krakow, Poland

AIDPORT Sp. z o.o.

🇵🇱

Skorzewo, Poland

Uniwersytecki Szpital Kliniczny Klinika

🇵🇱

Wrocław, Poland

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii

🇵🇱

Łódź, Poland

IPOFG - Lisboa

🇵🇹

Lisboa, Portugal

Champalimaud Foundation

🇵🇹

Lisboa, Portugal

GUZ of Moscow City Clinical Hospital n.a. S.P. Botkin

🇷🇺

Moscow, Russian Federation

Fed. State Budgetary Institution "Russian Scientific & Research Institute of Hemat. & Transfusiology of Fed. Medico-Bio. Agency

🇷🇺

Saint Petersburg, Russian Federation

State Medical University named after I.P. Pavlov

🇷🇺

Saint-Petersburg, Russian Federation

Hospital Universitario Virgen de la Victoria

🇪🇸

Malaga, Andalucía, Spain

Hospital Universitari Vall d'Hebron

🇪🇸

Barcelona, Barcelona [Barcelona], Spain

Hospital Duran I Reynals

🇪🇸

Hospitalet De Llobregat, Barcelona, Spain

Clinica Universidad de Navarra

🇪🇸

Pamplona, Navarra, Spain

Hospital Universitario Son Espases

🇪🇸

Palma De Mallorca, Palma De Mallorca(Baleares), Spain

Hospital Clinic de Barcelona

🇪🇸

Barcelona, Spain

Hospital General Universitario Gregorio Marañon

🇪🇸

Madrid, Spain

Hospital Universitario Infanta Leonor

🇪🇸

Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Clínico Universitario de Valencia

🇪🇸

Valencia, Spain

Kantonsspital Luzern

🇨🇭

Luzern 16, Luzern, Switzerland

Tri-Service General Hospital

🇨🇳

Taipei City, Taipei, Taiwan

Chang Gung Memorial Hospital - Chiayi

🇨🇳

Chiayi County, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

National Cheng-Kung Uni. Hosp.

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Chang Gung Memorial Hospital - Linkou

🇨🇳

Taoyuan City, Taiwan

Aberdeen Royal Infirmary

🇬🇧

Aberdeen, Aberdeen City, United Kingdom

Derriford Hospital

🇬🇧

Plymouth, Devon, United Kingdom

GenesisCare

🇬🇧

Newmarket, Suffolk, United Kingdom

Beatson West of Scotland Cancer Centre

🇬🇧

Glasgow, United Kingdom

City Hospital, Nottingham University Hospitals

🇬🇧

Nottingham, United Kingdom

Churchill Hospital

🇬🇧

Oxford, United Kingdom

GenesisCare, Windsor

🇬🇧

Windsor, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath